Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28687
Title: Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer's disease spectrum.
Austin Authors: Vilemagne, Victor L;Harada, Ryuichi;Doré, Vincent ;Furumoto, Shozo;Mulligan, Rachel S ;Kudo, Yukitsuka;Burnham, Samantha;Krishnadas, Natasha ;Bourgeat, Pierrick;Xia, Ying;Laws, Simon;Bozinovski, Svetlana ;Huang, Kun ;Ikonomovic, Milos D;Fripp, Jurgen;Yanai, Kazuhiko;Okamura, Nobuyuki;Rowe, Christopher C 
Affiliation: Molecular Imaging and Therapy
CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Australia
Department of Psychiatry, University of Pittsburgh, United States
School of Medical and Health Sciences, Edith Cowan University, Australia
Department of Pharmacology, Tohoku University School of Medicine, Japan
Cyclotron and Radioisotope Center, Tohoku University, Japan
Department of Molecular Imaging & Therapy, Austin Health
Institute of Development of Aging and Cancer, Tohoku University, Japan
Department of Neurology, University of Pittsburgh, United States
Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan
Issue Date: 27-Jan-2022
Date: 2022
Publication information: Journal of Nuclear Medicine 2022; jnumed.121.263255.
Abstract: Background: Neuroinflammatory reaction in Alzheimer's disease (AD) brains involves reactive astrocytes which overexpress monoamine oxidase-B (MAO-B). 18F-SMBT-1 is a novel F-18 PET tracer highly selective for MAO-B. We characterized the clinical performance of 18F-SMBT-1 PET across the Alzheimer's disease (AD) continuum as a potential surrogate marker of reactive astrogliosis Methods: We assessed 18F-SMBT-1 PET regional binding in 77 volunteers (76±5.5 y.o.; 41F/36M) across the AD continuum: 57 cognitively unimpaired controls (CN, 44 Aβ- & 13 Aβ+), 12 mild cognitively impaired (MCI, 9 Aβ- & 3 Aβ+), and 8 AD dementia patients (6 Aβ+ and 2 Aβ-). All participants also underwent Aβ and tau PET imaging, 3T MRI and neuropsychological evaluation. Tau imaging results were expressed in standard uptake value ratios (SUVR) using the cerebellar cortex as reference region, while Aβ burden was expressed in Centiloids. 18F-SMBT-1 outcomes were expressed as SUVR using the subcortical white matter as reference region. Results: 18F-SMBT-1 yielded high contrast images at steady state (60-80 min after injection). When compared to Aβ-CN, there were no significant differences in 18F-SMBT-1 binding in the Aβ-MCI group. Conversely, 18F-SMBT-1 binding was significantly higher in several cortical regions in the Aβ+AD group, but also was significantly lower in mesial temporal and basal ganglia. Most importantly, 18F-SMBT-1 binding was significantly higher in the same regions in Aβ+CN when compared to Aβ-CN. When all clinical groups were considered together, 18F-SMBT-1 was highly correlated with Aβ burden, and much less with tau burden. While in most cortical regions 18F-SMBT-1 was not correlated with brain volumetrics, regions known for high MAO-B concentrations presented a direct association with hippocampal and grey matter volumes, while the occipital lobe was directly associated with white matter hyperintensities. 18F-SMBT-1 binding was inversely correlated with MMSE and AIBL PACC in some neocortical regions such as the frontal cortex, lateral temporal and supramarginal gyrus. Conclusion: Cross-sectional human PET studies with 18F-SMBT-1, showed that Aβ+AD, but most importantly, Aβ+CN have significantly higher regional 18F-SMBT-1 binding than Aβ- CN. Moreover, in several regions in the brain, 18F-SMBT-1 retention was highly associated with Aβ load. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of Aβ accumulation, providing strong support for its use as surrogate marker of astrogliosis in the AD continuum.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28687
DOI: 10.2967/jnumed.121.263255
ORCID: 0000-0002-5832-9875
0000-0002-4355-7082
0000-0002-5374-2839
0000-0003-3910-2453
Journal: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
PubMed URL: 35086892
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35086892/
Type: Journal Article
Subjects: Alzheimer's disease
Amyloid
MAO-B
Molecular Biology
Molecular Imaging
Neurology
PET/CT
Reactive astrogliosis
Tau
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on May 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.